Drugs / UP-818-CC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07355621 | Feb 2022 → Jan 2023 | — | EnliTISA (Shanghai) Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UP-818-CC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07355621 ↗ |
| Route | Intravenous | “intravenous infusion” NCT07355621 ↗ |